The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Parkinson Kinetigraph – does it change the management of PD patients?
Objective: This pragmatic randomized open trial evaluated if the information from a Parkinson Kinetigraph (PKG) recording changed the management of PD patients at a visit…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease
Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)
Objective: To evaluate our current practice in the use of syringe drivers in End of Life Care in Parkinson’s Disease. Background: Palliative care in advanced…First-In-Human Study of LY3154207, a Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)
Objective: Evaluate the safety, tolerability, and plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of LY3154207 (LY) following oral dosing in healthy subjects (HS). Background: LY,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…The French NS-PARK/FCRIN network: a 5-year balance sheet
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity. Background: The French Clinical Research Infrastructure network FCRIN is…Trends in first line therapy for PD in Wales: A 16 year observational study
Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 32
- Next Page »